Introduction Limited data exist on the longer term clinical and haemodynamic impact of the HeartWare left ventricular assist device (HVAD®) when used as a bridge to heart transplantation. Patients who had a device longer than 3 months were reviewed.
Methods 26 patients had a HVAD implanted from 07/2009 to 07/2010 (mean age 46.8 years, 18 male, 5174 total days of support). Baseline and follow-up NYHA functional class, peak VO2 (bicycle exercise), right heart haemodynamics, biochemistry and mortality outcome were compared using paired t test. Results: 22/26 (85%) patients survived beyond 3 months. 4 patients died before (mean survival 40 days, 2 stroke and 2 multi-organ failure) and 2 died after (mean survival 173 days, 1 stroke, 1 right heart failure) discharge from hospital. 2 patients were transplanted (at 3 and 241 days after implant) and 1 had recovery of LV function. Follow-up data is available for 14/20 survivors (mean 197 days from implant). Significant results are shown in the Abstract 83 table 1. There was no significant change in peak VO2 (9.9±1.8 to 12.9±3.8, p=0.08), haemoglobin (12.7±1.7 to 12.1±1.2, p=0.3) or creatinine (122±41 to 105±38, p=0.19).
Conclusions The HVAD® results in significant improvement in functional class, right heart haemodynamics, cardiac output and sodium levels beyond 3 months of therapy. Ongoing randomised clinical trials will establish the long-term outcome of this device.
- Heart failure
- mechanical circulatory support
- ventricular assist device
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.